{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:35:10Z","timestamp":1773182110384,"version":"3.50.1"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The coronavirus disease 2019 (COVID-19) pandemic subverted people\u2019s lives and potentially affected the management and prognosis of pre-existing dermatoses. The study aims to identify factors influencing the outcomes of dermatoses during a rapid and widespread Omicron outbreak in China following the adjustment of the COVID-19 policy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This retrospective observational study involved outpatients visiting the dermatology department at a tertiary referral hospital in Beijing, China between December 2022 and February 2023. Demographics, COVID-19 characteristics, treatment modalities, and dermatosis outcomes were subjected to statistical analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The odds ratio (OR) for vitiligo aggravation during COVID-19 was 0.497 [95% confidence interval (CI): 0.254\u20130.973, <jats:italic>p<\/jats:italic>\u2009=\u20090.038] compared to total patients with various dermatoses. Psoriasis patients with a maximum body temperature (T<jats:sub>max<\/jats:sub>) over 38.6\u00b0C during COVID-19 were 2.833 times more likely to experience dermatosis aggravation (OR: 2.833 [1.029\u20137.803], <jats:italic>p<\/jats:italic>\u2009=\u20090.041). Moreover, autoimmune bullous disease (AIBD) patients receiving biologics treatment exhibited a reduced likelihood of aggravation during the COVID-19 outbreak (OR: 0 [0\u20130.531], <jats:italic>p<\/jats:italic>\u2009=\u20090.011).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Vitiligo exhibits lower aggravation rates during COVID-19 than other dermatoses. A higher body temperature during COVID-19 infection can increase the risk of psoriasis aggravation. Biologics treatment reduces the risk of AIBD aggravation during the COVID-19 outbreak.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1417358","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T11:51:19Z","timestamp":1717069879000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors influencing the outcomes of dermatoses during the COVID-19 outbreak in China: a retrospective study"],"prefix":"10.3389","volume":"11","author":[{"given":"Jing-Hui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si-Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Han","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Gang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40257-022-00675-2","article-title":"Cutaneous manifestations of SARS-CoV-2 infection","volume":"23","author":"Huynh","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1159\/000530746","article-title":"SARS-CoV-2 detection by digital polymerase chain reaction and immunohistochemistry in skin biopsies from 52 patients with different COVID-19-associated cutaneous phenotypes","volume":"239","author":"Marzano","year":"2023","journal-title":"Dermatology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.3390\/biomedicines10051183","article-title":"IL-33 enhances ACE2 expression on epidermal keratinocytes in atopic dermatitis: a plausible issue for SARS-CoV-2 transmission in inflamed atopic skin","volume":"10","author":"Lin","year":"2022","journal-title":"Biomedicines"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00403-020-02156-0","article-title":"Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations","volume":"313","author":"Gardu\u00f1o-Soto","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12016-017-8622-7","article-title":"Vitiligo: focus on clinical aspects, immunopathogenesis, and therapy","volume":"54","author":"Boniface","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/jocd.15550","article-title":"Various aspects of the relationship between vitiligo and the COVID-19 pandemic or SARS-CoV-2 vaccines: clinical pearls for dermatologists","volume":"22","author":"Aryanian","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e15014","DOI":"10.1111\/dth.15014","article-title":"Impact of treatment delays on vitiligo during the COVID-19 pandemic: a retrospective study","volume":"34","author":"Xu","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jdin.2021.11.004","article-title":"Temporary exacerbation of pre-existing psoriasis and eczema in the context of COVID-19 messenger RNA booster vaccination: a case report and review of the literature","volume":"6","author":"Phuan","year":"2022","journal-title":"JAAD Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e13632","DOI":"10.1111\/dth.13632","article-title":"Covid-19 and exacerbation of psoriasis","volume":"33","author":"Ozaras","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e14516","DOI":"10.1111\/dth.14516","article-title":"Does therapy with biological drugs influence COVID-19 infection? Observational monocentric prevalence study on the clinical and epidemiological data of psoriatic patients treated with biological drugs or with topical drugs alone","volume":"33","author":"Brazzelli","year":"2020","journal-title":"Dermatol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1080\/14712598.2021.1853698","article-title":"Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study","volume":"21","author":"Talamonti","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.25259\/IJDVL_551_2022","article-title":"Outcome of COVID-19 in patients with autoimmune bullous diseases","volume":"89","author":"De","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19968","article-title":"Flares and new related lesions of hidradenitis Suppurativa following COVID-19 vaccination: a retrospective cohort study of 250 patients in Greece","author":"Liakou","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"996288","DOI":"10.3389\/fmed.2022.996288","article-title":"Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic","volume":"9","author":"Maronese","year":"2022","journal-title":"Front Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1417358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T11:51:22Z","timestamp":1717069882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1417358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":14,"alternative-id":["10.3389\/fmed.2024.1417358"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1417358","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"article-number":"1417358"}}